Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01646762 · ClinicalTrials.gov registry record · Phase 2
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma
A Phase 2 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT01646762: Clinical Trial Phase 2 study, sponsored by Mayo Clinic.
NCT01646762 is a Phase 2 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01646762, a Phase 2 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
This phase II trial studies how well paclitaxel albumin-stabilized nanoparticle formulation works in treating patients with multiple myeloma that has returned or did not respond to treatment. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2012-11-05 |
| Est. Completion | 2015-10-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01646762
The ClinicalTrials.gov registry entry for NCT01646762 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01646762 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01646762 about?
NCT01646762 is a clinical study titled "Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma". This phase II trial studies how well paclitaxel albumin-stabilized nanoparticle formulation works in treating patients with multiple myeloma that has returned or did not respond to treatment. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in differen...
What is the current status of trial NCT01646762?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2012-11-05. Estimated completion is 2015-10-27.
What interventions are being tested in trial NCT01646762?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Paclitaxel Albumin-Stabilized Nanoparticle Formulation (DRUG).
Who is sponsoring clinical trial NCT01646762?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.